Literature DB >> 3964637

Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings.

A H Rahi, J L Hungerford, A I Ahmed.   

Abstract

This study documents for the first time light and electron microscopical changes in the retinal pigment epithelium (RPE) following treatment with high dose desferrioxamine for systemic iron overload. The changes include loss of microvilli from the apical surface, patchy depigmentation, vacuolation of the cytoplasm, swelling and calcification of mitochondria, and disorganisation of the plasma membrane. In addition, Bruch's membrane overlying degenerate RPE cells appeared abnormally thickened owing to the accumulation of large amounts of mature elastic fibres, pre-elastic oxytalan, and long spacing collagen. The specificity of these changes and the mechanism of toxicity are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3964637      PMCID: PMC1041018          DOI: 10.1136/bjo.70.5.373

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  11 in total

1.  THE EOG IN CHLOROQUINE AND OTHER RETINOPATHIES.

Authors:  P GOURAS; R D GUNKEL
Journal:  Arch Ophthalmol       Date:  1963-11

2.  [On iron-containing growth factors, sideramines, and their antagonists, the iron-containing antibiotics, sideromycins].

Authors:  H BICKEL; E GAEUMANN; W KELLER-SCHIERLEIN; V PRELOG; E VISCHER; A WETTSTEIN; H ZAEHNER
Journal:  Experientia       Date:  1960-04-15

3.  Elastic and precursor fibres in the normal human eye.

Authors:  R A Alexander; A Garner
Journal:  Exp Eye Res       Date:  1983-02       Impact factor: 3.467

4.  Retinal detachment in the cat: the pigment epithelial-photoreceptor interface.

Authors:  D H Anderson; W H Stern; S K Fisher; P A Erickson; G A Borgula
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-07       Impact factor: 4.799

5.  Treatment of experimental siderosis bulbi, vitreous hemorrhage, and corneal blood staining with deferoxamine.

Authors:  J B Wise
Journal:  Arch Ophthalmol       Date:  1966-05

6.  Chloroquine retinopathy in the rhesus monkey.

Authors:  A R Rosenthal; H Kolb; D Bergsma; D Huxsoll; J L Hopkins
Journal:  Invest Ophthalmol Vis Sci       Date:  1978-12       Impact factor: 4.799

7.  Copper metabolism in retinitis pigmentosa patients.

Authors:  S S Rao; M Satapathy; A Sitaramayya
Journal:  Br J Ophthalmol       Date:  1981-02       Impact factor: 4.638

8.  The effects of iodate and iodoacetate on the retinal adhesion.

Authors:  F S Ashburn; A R Pilkerton; N A Rao; G E Marak
Journal:  Invest Ophthalmol Vis Sci       Date:  1980-12       Impact factor: 4.799

9.  Ocular toxicity of high-dose intravenous desferrioxamine.

Authors:  S C Davies; R E Marcus; J L Hungerford; M H Miller; G B Arden; E R Huehns
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

10.  Lens opacities in thalassemia.

Authors:  S E Bloomfield; A L Markenson; D R Miller; C M Peterson
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1978 May-Jun       Impact factor: 1.402

View more
  19 in total

1.  Rapid development of severe toxic retinopathy associated with continuous intravenous deferoxamine infusion.

Authors:  T Y Y Lai; G K Y Lee; W-M Chan; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

2.  Prochelators triggered by hydrogen peroxide provide hexadentate iron coordination to impede oxidative stress.

Authors:  Marina G D Leed; Natalie Wolkow; David M Pham; Catherine L Daniel; Joshua L Dunaief; Katherine J Franz
Journal:  J Inorg Biochem       Date:  2011-06-12       Impact factor: 4.155

3.  EOG as a monitor of desferrioxamine retinal toxicity.

Authors:  Rudy R Hidajat; Jan L McLay; David H Goode; Ruth L Spearing
Journal:  Doc Ophthalmol       Date:  2004-11       Impact factor: 2.379

4.  Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity.

Authors:  Kelly M Bui; SriniVas R Sadda; Hani Salehi-Had
Journal:  Digit J Ophthalmol       Date:  2017-02-13

5.  Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Authors:  R B Raffa; R J Tallarida
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

6.  Multimodal imaging in a case of deferoxamine-induced maculopathy.

Authors:  Rony Gelman; Szilard Kiss; Stephen H Tsang
Journal:  Retin Cases Brief Rep       Date:  2014

Review 7.  Retinal abnormalities in β-thalassemia major.

Authors:  Devang L Bhoiwala; Joshua L Dunaief
Journal:  Surv Ophthalmol       Date:  2015-08-29       Impact factor: 6.048

8.  Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity.

Authors:  E E Voest; J P Neijt; J E Keunen; A W Dekker; B S van Asbeck; J W Nortier; F E Ros; J J Marx
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Contrast sensitivity in patients with Beta-thalassemia major and sickle cell disease under regular transfusions and treatment with desferrioxamine.

Authors:  Spyridon Gorezis; Ioannis Asproudis; Nikolaos Chalasios; Aikaterini Karali; Elena Tsanou; Dimitrios Peschos; Aikaterini Christodoulou; Miltiadis Aspiotis
Journal:  Open Ophthalmol J       Date:  2010-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.